The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
The association between HLA-C*06:02 and age of psoriasis onset on response to biologic treatment
Biologic treatments have been shown to be highly effective for some individuals with psoriasis, but response to biologic treatment may vary.1 There are no clear guidelines on biologic selection, which can lead to a trial-and-error approach to treatment.1 Here, we summarize a study published by Alabas et al. in the British Journal of Dermatology investigating the association between HLA-C*06:02 and the age of psoriasis onset, with response to biologic treatment.1
Study design1
-
Data were analyzed for patients ≥16 years of age, on a first course of adalimumab, etanercept, secukinumab, or ustekinumab with ≥6 months’ follow-up and who were registered to the British Association of Dermatologist Biologics and Immunomodulators Register (BADBIR) between 2007 and 2022 with HLA-C*06:02 information available.
-
Early-onset psoriasis was defined as patients who developed psoriasis ≤ 40 years of age and late-onset as patients who developed psoriasis >40 years of age.
-
Only patients aged 50 years or above at enrollment were categorized with age of onset.
-
Response to biologic treatment was analyzed in terms of biologic survival, defined as discontinuation due to ineffectiveness or adverse events.
Patient population1
- In total, 4,250 patients were were stratified by age at psoriasis onset (2,929 were classified with early-onset psoriasis and 1,321 with late-onset psoriasis).
- A total of 3,094 patients were stratified by HLA-C*06:02 status (1,603 were HLA-C*06:02 positive and 1,491 were HLA-C*06:02 negative).
Key findings1
- Age of psoriasis onset did not affect treatment discontinuation due to biologic ineffectiveness.
- Patients who were positive for HLA-C*06:02 were less likely to discontinue ustekinumab due to ineffectiveness compared with those who were HLA-C*06:02 negative (Table 1).
- There was no difference in time until discontinuation due to adverse events when comparing the age-of-onset groups or HLA-C*06:02 status (Table 1).
Table 1. Adjusted hazard ratios for ineffectiveness and adverse events for adalimumab, etanercept, secukinumab, and ustekinumab *
|
AE, adverse event; aHR, adjusted hazard ratio. *Adapted from Alabas et al.1 |
||||
|
|
Ineffectiveness |
AEs |
||
|---|---|---|---|---|
|
aHR |
P value |
aHR |
P value |
|
|
Age at psoriasis onset |
|
|
|
|
|
Early-onset (reference) |
||||
|
Adalimumab |
1.14 |
0.180 |
0.81 |
0.077 |
|
Etanercept |
1.13 |
0.410 |
0.76 |
0.241 |
|
Secukinumab |
1.20 |
0.394 |
1.14 |
0.619 |
|
Ustekinumab |
0.96 |
0.754 |
1.24 |
0.163 |
|
HLA-C*06:02 |
|
|
|
|
|
HLA-C*06:02 negative (reference) |
||||
|
Adalimumab |
0.85 |
0.083 |
1.13 |
0.356 |
|
Etanercept |
0.98 |
0.864 |
1.62 |
0.057 |
|
Secukinumab |
1.00 |
1.000 |
1.71 |
0.297 |
|
Ustekinumab |
0.56 |
<0.001 |
0.81 |
0.279 |
|
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content